Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 4/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424658 | 0.75 | AKR1B1 (0.31) | — | |
| SCHEMBL1275073 | 0.73 | ARG1 (0.48) | SLC1A1ARG1ARG2ALDH1A1ALOX15 | |
| SCHEMBL788420 | 0.73 | ARG1 (0.48) | SLC1A1ARG1ARG2ALDH1A1ALOX15 | |
| SCHEMBL788419 | 0.73 | ARG1 (0.48) | SLC1A1ARG1ARG2ALDH1A1ALOX15 | |
| SCHEMBL2017576 | 0.70 | P2RY10 (0.56) | — | |
| SCHEMBL22219423 | 0.70 | P2RY10 (0.56) | — | |
| SCHEMBL30244695 | 0.70 | P2RY10 (0.56) | — | |
| SCHEMBL21067706 | 0.70 | P2RY10 (0.56) | — | |
| SCHEMBL13863415 | 0.70 | P2RY10 (0.56) | — | |
| SCHEMBL29715574 | 0.70 | P2RY10 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377099-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | ImmunoVaccine Technologies Inc. (CA) | 2018-09-26 | — | — | EP | disclosed |
| US-9567336-B2 | Conjugated TLR7 and/or TLR8 and TLR2 agonists | INVIVOGEN (FR) | 2017-02-14 | — | — | US | disclosed |
| EP-2769738-B1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | INVIVOGEN (FR) | 2016-07-20 | — | — | EP | disclosed |
| US-9295732-B2 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | INVIVOGEN (FR) | 2016-03-29 | — | — | US | disclosed |
| EP-2732825-B1 | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist | INVIVOGEN (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | CAYLA (FR) | 2014-08-28 | — | — | US | disclosed |
| EP-2769738-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | Invivogen (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | CAYLA (FR) | 2014-05-22 | — | — | US | disclosed |
| EP-2732825-A1 | Conjugated TLR7 and/or TLR8 and TLR2 agonists | Invivogen (FR) | 2014-05-21 | — | — | EP | disclosed |
| WO-2009137103-A2 | ANTI-CANCER/ANTI-VIRAL COMPOUNDS AND METHODS OF USE | OURTH DONALD D (US) | 2009-11-12 | — | — | WO | disclosed |
| US-6074650-A | INDUCTION OF CYTOTOXIC LYMPHOCYTES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| US-6024964-A | ANTIBODIES AND ANTIGENS WITH MEMBRANE ANCHORING | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | TLR7, TLR8, TLR9 | SLC1A1 4272/4885ARG1 1565/4885ARG2 1341/4885 |
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | TLR7, TLR8, TLR9 | SLC1A1 3624/4885ARG1 830/4885ARG2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.